Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination

Fan, Wei; Sun, Wei; Wong, Thian‐Sze; Gao, Wei; Wen, Yi; Wei, Jia; Wei, Yi; Wen, Wang

doi:10.1186/s13046-016-0295-1

Cited by 22 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on this classification of human Tregs, our study provided evidence to support the notion of heterogeneous Treg subsets in HNSCC patients ( Sun et al , 2014 , 2015, 2016 , ). We showed that aTreg cells, as the predominant cell population among tumour-infiltrating Foxp3 + Treg cells, accelerate disease progression by suppressing TAA immunity in patients with HNSCC ( Sun et al , 2016 ; Wei et al , 2016 ). To determine whether TSN-exposed M2-like macrophages contribute to an increase in aTreg cells, we analysed the subsets of induced Treg cells.…”

Section: Discussionmentioning

confidence: 95%

A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma

Sun

Wei

et al. 2017

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Background:Foxp3+ regulatory T (Treg) cells and M2 macrophages are associated with increased tumour progression. However, the interaction between Treg cells and M2 macrophages remains unclear.Methods:The expression of FoxP3 and CD163 was detected by immunohistochemistry in 65 cases of laryngeal squamous cell carcinoma (LSCC). In vitro, the generation of activated Treg (aTreg) cells and M2 macrophages by interactions with their precursor cells were analysed by flow cytometry and ELISA. In vivo, the antitumour effects were assessed by combined targeting aTreg cells and M2 macrophages, and intratumoural immunocytes were analysed by flow cytometry.Results:In LSCC tissue, accumulation of aTreg cells and M2 macrophages predicted a poor prognosis and were positively associated with each other. In vitro, aTreg cells were induced from CD4+CD25− T cells by cancer cell-activated M2-like macrophages. Consequently, these aTreg cells skewed the differentiation of monocytes towards an M2-like phenotype, thereby forming a positive-feedback loop. Combined targeting aTreg cells and M2 macrophages led to potent antitumour immunity in vivo.Conclusions:The positive-feedback loop between aTreg cells and M2 macrophages is essential to maintain or promote immunosuppression in the tumour microenvironment and may be a potential therapeutic target to inhibit tumour progression.

show abstract

Section: Discussionmentioning

confidence: 95%

A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma

Sun

Wei

et al. 2017

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another interesting preclinical approach is the usage of tumour cell lysates [ 173 ]. In this study, DCs pulsed with heat-treated tumour cell lysates of laryngeal cancer could induce anti-tumour immunity against a cell line.…”

Section: Tumour-associated Antigens (Taas)mentioning

confidence: 99%

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

Witzleben

Wang

Laban

et al. 2020

Cells

View full text Add to dashboard Cite

Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of malignant tumours typically caused by alcohol and tobacco consumption, although an increasing number of HNSCC arise due to persistent infection with high-risk human papilloma virus (HPV). The treatment of HNSCC remains challenging, and the first-line setting is focused on surgery and chemoradiotherapy. A substantial proportion of HNSCC patients die from their disease, especially those with recurrent and metastatic disease. Among factors linked with good outcome, immune cell infiltration appears to have a major role. HPV-driven HNSCC are often T-cell rich, reflecting the presence of HPV antigens that are immunogenic. Tumour-associated antigens that are shared between patients or that are unique to an individual person may also induce varying degrees of immune response; studying these is important for the understanding of the interaction between the host immune system and the cancer. The resulting knowledge is critical for the design of better immunotherapies. Key questions are: Which antigens lead to an adaptive immune response in the tumour? Which of these are exploitable for immunotherapy? Here, we review the current thinking regarding tumour antigens in HNSCC and what has been learned from early phase clinical trials.

show abstract

“…The principle of DC vaccine preparation is to collect lymphocytes from peripheral blood, induce them into DC in vitro, and present tumor antigens to DCs, thereby providing a large number of these cells for active immunotherapy (Dannull et al, 2013). Tumor antigen presentation to DC can be accomplished in a variety of ways (Osada et al, 2015;Wei et al, 2016). A new method was developed to present autologous tumor antigens to the cytoplasm of DCs.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov

Wang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Comprehensively evaluate the immunotherapeutic clinical trials and provide reference for melanoma treatment and research. Methods: The website of ClinicalTrials.gov was searched to retrieve and download all registered clinical trials for melanoma immunotherapy on August 1 (updated on August 25), 2019. All registration trials met the inclusion criteria were collected regardless of the type of study, the status of recruitment, and the results of the study. The general characteristics, methodological characteristics, and the types of immunotherapeutic drugs included of these trials were analyzed. Results: Finally, 242 eligible trials were included and evaluated. Of them, 30.6% were completed, 16.9% were terminated, and two were withdrawn; 77.7% recruited less than 100 participants; 30.5% were randomized; 45.5% was single group assignment; 88.8% were not masked; the primary purpose was treatment; 44.2% had data on monitoring committees; 27.7% used US FDA-regulated immunization drugs; 78.5% without results posted; 43.0% were sponsored by the industry. Immunological checkpoint inhibitors were most often studied, with 53.6% of the trials involving PD-1, the most commonly studied was Nivolumab. Conclusions: Currently, most of the registered clinical trials for melanoma immunotherapy were interventional open-label trials. Most immunotherapy research hotspots were in the FDA-regulated drug product, and a few trials reported available test results. It is necessary to strengthen the supervision of results and explore and disseminate more effective and safe immunotherapy methods.

show abstract

Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination

Cited by 22 publications

References 38 publications

A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma

A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

Comprehensive Survey of Clinical Trials Registration for Melanoma Immunotherapy in the ClinicalTrials.gov

Contact Info

Product

Resources

About